Search
Soybean oil
go.drugbank.com/drugs/DB09422ApprovedInvestigationalIt is used as a cooking oil and lipid emulsion for parenteral nutrition in clinical settings. Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use. … It is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsaturated fat, and 58 g of polyunsaturated fat.
Mixtures: NUTRİCLİN N4-550 E IV İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1000 ML, NUTRİCLİN N4-550 E IV İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1500 MLProducts: LIPOFUNDIN 20 %N, LIPOFUNDIN 10 %NCiltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development … It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000,[L40749] and is variable in its presentation - some patients may remain entirely asymptomatic, while others may experience
Synonyms: Autologous bi-epitope BCMA-targeted CAR T-cellsLisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL). … [A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period.
Categories: CD19-Directed Genetically Modified Autologous T-cell ImmunotherapiesV-ATPase Subunits
go.drugbank.com/bio_entities/BE0009961TargetHumansIn renal intercalated cells, can partially compensate the lack of ATP6V1B1 and mediate secretion of protons (H+) into the urine under base-line conditions but not in conditions of acid load (By similarity … In certain cell types, can be exported to the plasma membrane, where it is involved in the acidification of the extracellular environment (By similarity).
Polypeptides: V-type proton ATPase subunit e 1, V-type proton ATPase subunit E 1Synonyms: V-ATPase subunit e 1, V-ATPase subunit E 1Nuclear receptor coactivator 1
go.drugbank.com/bio_entities/BE0003728TargetHumansPlays a central role in creating multisubunit coactivator complexes that act via remodeling of chromatin, and possibly acts by participating in both chromatin remodeling and recruitment of general transcription … Also involved in coactivation mediated by STAT3, STAT5A, STAT5B and STAT6 transcription factors.
Synonyms: Class E basic helix-loop-helix protein 74Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigational[A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. … Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains.
Synonyms: N-formimidoylthienamycin, N-formimidoyl thienamycinMixtures: IMIPENEM E CILASTATINA SUN, IMIPENEM E CILASTATINA SUNRetinol dehydrogenase 16
go.drugbank.com/bio_entities/BE0011917EnzymeHumansOxidoreductase with a preference for NAD. Oxidizes all-trans-retinol, 9-cis-retinol, 11-cis-retinol and 13-cis-retinol to the corresponding aldehydes (PubMed:10329026, PubMed:12534290, PubMed:9677409). Has higher activity towards CRBP-bo...
Synonyms: hRDH-ELapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalIt was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.
Synonyms: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamineCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesFibronectin receptor
go.drugbank.com/bio_entities/BE0010279TargetHumansIt recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. … Integrins alpha-1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence G-F-P-G-E-R in collagen.
Synonyms: CD49 antigen-like family member ECilastatin
go.drugbank.com/drugs/DB01597ApprovedInvestigational[L7628] A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam].[L4894] … Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4.
Synonyms: (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine, (Z)-7-((R)-2-Amino-2-carboxy-ethylsulfanyl)-2-[((S)-2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acidMixtures: IMIPENEM E CILASTATINA SUN, IMIPENEM E CILASTATINA SUN